Eosinophilia Induced by Biosimilar Adalimumab (CinnoRA) in a Patient with Psoriasis and Psoriatic Arthritis: A Case Report.

IF 2.2 4区医学 Q3 DERMATOLOGY

Clinical, Cosmetic and Investigational Dermatology Pub Date : 2025-09-04 eCollection Date: 2025-01-01 DOI:10.2147/CCID.S546208

Roya Saedpanah, Atiye Rashidi, Alireza Firooz

{"title":"Eosinophilia Induced by Biosimilar Adalimumab (CinnoRA) in a Patient with Psoriasis and Psoriatic Arthritis: A Case Report.","authors":"Roya Saedpanah, Atiye Rashidi, Alireza Firooz","doi":"10.2147/CCID.S546208","DOIUrl":null,"url":null,"abstract":"Background: Psoriasis is a chronic inflammatory skin disorder that can significantly impact quality of life. Biologic therapies, such as TNF-alpha inhibitors, have improved clinical outcomes but may rarely cause hematologic abnormalities, including eosinophilia. Eosinophilia is uncommon but can be associated with allergic reactions or organ involvement.Case presentation: We report a 33-year-old male with psoriasis and psoriatic arthritis who developed asymptomatic marked eosinophilia after eight doses of biosimilar adalimumab (CinnoRA). Baseline peripheral blood eosinophil percentage was 3.2%, which increased to 19.9% during therapy. Alternative causes, including parasitic infection, allergy, and hematologic disease, were excluded. CinnoRA was discontinued, and eosinophil counts normalized during follow-up.Conclusion: This case illustrates that unexplained eosinophilia can occur during TNF-alpha inhibitor therapy. While routine monitoring is not universally recommended based on a single case, clinicians should consider eosinophilia as a possible adverse reaction, especially in symptomatic patients or those with persistently elevated counts.","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"2183-2188"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12418804/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical, Cosmetic and Investigational Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CCID.S546208","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Psoriasis is a chronic inflammatory skin disorder that can significantly impact quality of life. Biologic therapies, such as TNF-alpha inhibitors, have improved clinical outcomes but may rarely cause hematologic abnormalities, including eosinophilia. Eosinophilia is uncommon but can be associated with allergic reactions or organ involvement.

Case presentation: We report a 33-year-old male with psoriasis and psoriatic arthritis who developed asymptomatic marked eosinophilia after eight doses of biosimilar adalimumab (CinnoRA). Baseline peripheral blood eosinophil percentage was 3.2%, which increased to 19.9% during therapy. Alternative causes, including parasitic infection, allergy, and hematologic disease, were excluded. CinnoRA was discontinued, and eosinophil counts normalized during follow-up.

Conclusion: This case illustrates that unexplained eosinophilia can occur during TNF-alpha inhibitor therapy. While routine monitoring is not universally recommended based on a single case, clinicians should consider eosinophilia as a possible adverse reaction, especially in symptomatic patients or those with persistently elevated counts.

Abstract Image

查看原文本刊更多论文

生物仿制药阿达木单抗（CinnoRA）在银屑病和银屑病关节炎患者中诱导嗜酸性粒细胞增多：1例报告。

背景：牛皮癣是一种慢性炎症性皮肤病，可显著影响生活质量。生物疗法，如tnf - α抑制剂，改善了临床结果，但可能很少引起血液学异常，包括嗜酸性粒细胞增多。嗜酸性粒细胞增多症并不常见，但可能与过敏反应或器官受累有关。病例介绍：我们报告了一位患有银屑病和银屑病关节炎的33岁男性患者，在服用8剂阿达木单抗（CinnoRA）生物仿制药后出现无症状的明显嗜酸性粒细胞增多。基线外周血嗜酸性粒细胞百分比为3.2%，治疗期间增加到19.9%。排除了其他原因，包括寄生虫感染、过敏和血液疾病。CinnoRA停用，随访期间嗜酸性粒细胞计数恢复正常。结论：本病例说明在tnf - α抑制剂治疗期间可能发生不明原因的嗜酸性粒细胞增多。虽然常规监测并不普遍推荐基于单个病例，临床医生应考虑嗜酸性粒细胞增多作为一个可能的不良反应，特别是在有症状的患者或那些持续升高的计数。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical, Cosmetic and Investigational Dermatology Medicine-Dermatology

CiteScore

2.80

自引率

4.30%

发文量

353

审稿时长

16 weeks

期刊介绍： Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. Normal and pathological processes in skin development and aging, their modification and treatment, as well as basic research into histology of dermal and dermal structures that provide clinical insights and potential treatment options are key topics for the journal. Patient satisfaction, preference, quality of life, compliance, persistence and their role in developing new management options to optimize outcomes for target conditions constitute major areas of interest. The journal is characterized by the rapid reporting of clinical studies, reviews and original research in skin research and skin care. All areas of dermatology will be covered; contributions will be welcomed from all clinicians and basic science researchers globally.